Cancer Medicine (Oct 2021)
Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
- David Foureau,
- Manisha Bhutani,
- Fei Guo,
- Katherine Rigby,
- Marina Leonidas,
- Elise Tjaden,
- Andee Fox,
- Shebli Atrash,
- Barry Paul,
- Peter M. Voorhees,
- Saad Z. Usmani
Affiliations
- David Foureau
- Immune Monitoring Core Laboratory Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- Manisha Bhutani
- Department of Hematologic Oncology Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- Fei Guo
- Immune Monitoring Core Laboratory Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- Katherine Rigby
- Department of Hematologic Oncology Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- Marina Leonidas
- Immune Monitoring Core Laboratory Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- Elise Tjaden
- Department of Hematologic Oncology Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- Andee Fox
- Department of Hematologic Oncology Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- Shebli Atrash
- Department of Hematologic Oncology Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- Barry Paul
- Department of Hematologic Oncology Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- Peter M. Voorhees
- Department of Hematologic Oncology Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- Saad Z. Usmani
- Department of Hematologic Oncology Levine Cancer InstituteAtrium Health Charlotte North Carolina USA
- DOI
- https://doi.org/10.1002/cam4.4254
- Journal volume & issue
-
Vol. 10,
no. 20
pp. 6933 – 6936
Abstract
No abstracts available.Keywords
